Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients.

ABSTRACT:

Introduction

Corticosteroids are one of the most promising therapeutic agents for critically ill patients with coronavirus disease 2019 (COVID-19). Despite emerging data, assessed populations and regimens vary, and there are patient subgroups whose response to steroids remains unclear. We aimed to evaluate the outcomes of COVID-19 patients admitted to the intensive care unit (ICU) and treated with a short dexamethasone course to determine which patient categories derive the highest benefit.

Methods

A retrospective cohort study was conducted using a prospectively collected single-center ICU database (April 1-October 1, 2020). Adult COVID-19 patients were assigned to dexamethasone (12 mg × 3 days) and usual care groups. Patient, management, and outcome data were extracted. The

SUBMITTER: Oganesyan A 

PROVIDER: S-EPMC8645403 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature